MRx-4DP0004 is under clinical development by 4D Pharma and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MRx-4DP0004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MRx-4DP0004 overview

MRx-4DP0004 is under development for the treatment of severe neutrophilic asthma. The therapeutic candidate is administered through oral route. It constitutes naturally occurring single strain live bacteria. It is developed based on MicroRx technology.

It was also under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

4D Pharma overview

4D Pharma formerly 4D Pharma Ltd, is a drug development company. The company discovers and develops bio therapeutics and therapies for the treatment of cancer, gastro-intestinal, autoimmune and CNS diseases. Its pipeline product candidates include MRx0518, a neoadjuvant monotherapy for solid tumors and pancreatic cancer; Blautix, for the treatment of irritable bowel syndrome; MRx-4DP0004 against allergic asthma and coronavirus; and MRx0029 to treat neurodegeneration. It is also evaluating therapies in the areas of oncology, gastro-intestinal, respiratory, and other therapeutic areas. 4D Pharma also offers clinical development services. The company has operational presence in Ireland and Spain. 4D Pharma is headquartered in Leeds, Yorkshire, the UK.

For a complete picture of MRx-4DP0004’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.